There is a well-known therapeutic antibody, such as bevacizumab, which targets vascular endothelial growth factor (VEGF), has been approved for use as a first-line treatment for metastatic colorectal cancer in 2004 [9]. Here, VEGFA is linked to metastatic colorectal cancer.